Related Experiment Video
Updated: Jan 21, 2026

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
A Pt(IV) prodrug-gating MOF incorporating copper peroxide and ruthenium complex for NIR-mediated synergistic
Romaine Parker1, Rajeshkumar Anbazhagan1, Chia-Yu Kuo1
1Institute of Clinical Pharmacy and Pharmaceutical Sciences, School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan. thchen@gs.ncku.edu.tw.
Abstract:
The development of efficient and multifunctional nanosystems is crucial for enhancing anticancer therapy. The incorporation of therapeutic agents in nanocarriers often results in premature drug release, leading to unsatisfactory therapeutic effects. To overcome these challenges, a nanosystem, MOF@Cu/Ru/Pt (MOF = metal-organic framework UiO-67(bpy), bpy = bipyridine, Cu = copper peroxide, Ru = [Ru(bpy)3]2+, and Pt = Pt(IV) prodrug), is synthesized. The chemotherapeutic Pt(IV) prodrug can coordinate with the MOF and act as a gating agent for the confinement and the glutathione-responsive controlled release of Cu and Ru species, respectively, for chemodynamic/photothermal and photodynamic therapies. Upon exposure to near-infrared irradiation, this material facilitates the enhanced generation of reactive oxygen species and a temperature rise. The in vitro studies of MOF@Cu/Ru/Pt demonstrate excellent biocompatibility in normal cells and remarkable therapeutic efficacy in 4T1 cancer cells, attributed to the synergistic anticancer effects.
Related Concept Videos
Prodrugs
Prodrugs help overcome...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Electron Transport Chain: Complex III and IV
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism

